ATLASAtrium Therapeutics (RNA) earnings date: Nov 12, 2026
Atrium Therapeutics (RNA) reports earnings for the quarter ended Sep 30, 2026 on Thu, Nov 12, 2026. Analysts expect EPS of -$1.14.
Source: company filings and exchange data · Updated Nov 2, 2026
ATLAS view on RNA
| Last price | $8.27 (+0.1%) |
|---|---|
| Normal 1-day range (±1σ) | ±3.2% |
| Earnings beat history | Beat the EPS estimate in 2 of the last 4 reports |
These figures come from the same calibrated model and valuation as the Atrium Therapeutics stock page. They describe an ordinary period, not the earnings reaction itself, which is usually wider and can go either way.
Atrium Therapeutics reports on Nov 12, 2026. One email the day before, with ATLAS’s read on Atrium Therapeutics. You can switch it off at any time.
Alert me before RNA reportsFree to start. Creating an account takes under a minute.
RNA earnings at a glance
| Next report (confirmed) | Thu, Nov 12, 2026 |
|---|---|
| Time | Not stated |
| Period | Quarter ended Sep 30, 2026 |
| EPS estimate | -$1.14 |
| Last report | Aug 13, 2026 · Miss |
| Beat rate (last 4 reports) | 2 of 4 (50%) |
| Average EPS surprise | -24.6% |
| Average move around a report | ±1.6% (last 4) |
| Sector | Healthcare · Biotechnology |
Atrium Therapeutics earnings history: last 4 reports
Atrium Therapeutics last reported on Aug 13, 2026: EPS of -$1.18 against an estimate of -$0.64 (-84.4% surprise), a miss.
| Report date | EPS est. | EPS actual | Surprise | Result | Move* |
|---|---|---|---|---|---|
| Aug 13, 2026 | -$0.64 | -$1.18 | -84.4% | Miss | +5.5% |
| May 14, 2026 | -$1.05 | -$0.97 | +7.6% | Beat | -0.5% |
| Feb 23, 2026 | -$1.26 | -$1.59 | -26.2% | Miss | -0.1% |
| Jan 16, 2026 | $4.47 | $4.67 | +4.5% | Beat | -0.2% |
*Move: change in the closing price from the last close before the report day to the close the day after it, so it captures the reaction whether the company reported before the open or after the close.
Get the full ATLAS analysis for RNA
See the fair value, the probability range and the earnings history of Atrium Therapeutics on its ATLAS page.
Atrium Therapeutics (RNA) stock analysisPlans from €3.99 a month.
Atrium Therapeutics earnings: frequently asked questions
When does Atrium Therapeutics (RNA) report earnings?
Atrium Therapeutics is scheduled to report on Thursday, November 12, 2026 (the time of day has not been stated). ATLAS only shows a confirmed date when the company or the exchange data provides one; check the investor relations page for the call details.
What is the EPS estimate for RNA?
The consensus EPS estimate for the quarter ended Sep 30, 2026 is -$1.14 per share (USD). Estimates can change before the report.
How often does RNA beat earnings estimates?
Of its last 4 reports with a recorded result, Atrium Therapeutics beat the EPS estimate 2 times; the average surprise was -24.6%. Past results do not predict the next one.
How much does RNA move around earnings?
Over its last 4 reports the stock moved an average of 1.6% (absolute, from the close before the report day to the close after it), and finished higher 1 of 4 times.
Did Atrium Therapeutics beat earnings estimates last quarter?
Atrium Therapeutics last reported on Aug 13, 2026: EPS of -$1.18 against an estimate of -$0.64 (-84.4% surprise), a miss.
How much does RNA usually move in a day?
On a normal trading day the ATLAS model puts RNA’s one-day range at about ±3.2%, with a 50% chance of closing higher. This is not an options-implied earnings move; earnings days are usually wider.
Also reporting on Thu, Nov 12, 2026
Educational information, not investment advice. Disclaimer